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Over the past 50 y, research in skin biology and diseases
has changed dramatically. These changes include (i)
who is doing the research, from M.D. clinician derma-
tologists to predominantly Ph.D. research scientists and
full-time or nearly full-time M.D. and M.D.^Ph.D.
scientists, (ii) where, from small laboratories in the
U.S.A. to large laboratories and multiinvestigator colla-
borations worldwide, (iii) what, from a focus on com-
mon skin diseases to an emphasis on understanding
basic processes in skin, both in normal and disease
states, and (iv) how, from patient observations, histol-
ogy, and clinical immunology to cell and tissue culture,
molecular biology and genetics, genomics and proteo-
mics. Financing of this research has also changed, from
the use of clinical surplus funds supplemented by U.S.
government (National Institutes of Health,Veterans Ad-
ministration, and other) monies to a greater depen-
dence on government and private (pharmaceutical
industry and philanthropy) funding. The future, fund-
ing issues aside, promises great advances with trans-
lation of basic knowledge to the diagnosis, preven-
tion, and treatment of skin diseases. Key words: NIH/
cutaneous biology/dermatologist/scientist/qenomies/proteomics.
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I
nthe last 50 y, research in cutaneous biology and diseases of
the skin has changed signi¢cantly and is continuing to
change. In this review, I will use the reporter’s approach by
looking at a modi¢cation of the ¢veWs ^ who, what, when,
where, and why. The why is clear-cut for all of those inter-
ested in cutaneous biology and I will not discuss that any further.
The when has been de¢ned as the last 50 y but I will make some
comments concerning future directions as well. I will add an ad-
ditional category of how.
WHO
In the 1950s, most research in the area of cutaneous biology was,
in fact, dermatology research. It was done by dermatologist phy-
sicians who were primarily clinicians. These individuals spent
much of their time seeing patients with the diseases in which
they were interested and training resident physicians but then
went to the laboratory to do research that was often disease or-
iented. The other members of the research team sometimes in-
cluded Ph.D. trained scientists but in only a small number of
cases were Ph.D. scientists the heads of the laboratories or re-
search teams. There were very few, if any, physicians who spent
the overwhelming majority of their time doing research. In the
1960s and the 1970s, a greater number of physicians who spent
most of their time doing research, many of whom held the com-
bined M.D. and Ph.D. degrees, began to appear in the ¢eld. Dur-
ing this time, also, more Ph.D. trained scientists became involved
in research and more of them became heads of the projects and
heads of laboratories. In the 1980s and in the last decade, this trend
has accelerated.We now see, at least in terms of National Insti-
tutes of Health (NIH) supported cutaneous biology research, that
the majority of projects and the majority of laboratories are
headed by Ph.D. scientists. M.D. Ph.D. scientists remain a signif-
icant component and have maintained a steady in£uence over the
last 20 y. Clinicians now rarely head more basic projects but are
often collaborators, particularly when disease pathogenesis is
being investigated. In the last decade and more speci¢cally in
the last 2 or 3 y, there has been an increasing emphasis on transla-
tional research as well as epidemiology and outcomes research.
This ¢eld is still relatively small and is predominantly an area
of M.D. investigators with public health credentials, either an
M.P.H. or Ph.D. in epidemiology and related ¢elds. In the future,
it is likely that this last area will grow the most, at least in propor-
tion to its modest beginnings, but that the overall cutaneous
biology enterprise will continue to be driven by Ph.D. and
M.D.Ph.D. scientists looking at basic cutaneous biology pro-
cesses and disease pathogenesis. There will always be a place for
the clinician scientist who is necessary in order for an appropriate
understanding of how the cutaneous biology ¢ndings relate to
the disease process in the patient and to the potential for the de-
velopment of therapeutic and/or preventive interventions.
In the 1950s, most cutaneous biology research took place in
small laboratories. These usually consisted of the principal inves-
tigator, one or two additional scientists, and one or two techni-
cians or fewer individuals. This slowly gave way over the next 20
to 30 y to the development of larger laboratories where the prin-
cipal investigator, now more often a Ph.D. scientist or an M.D. or
M.D.^Ph.D. scientist spending essentially full time in research,
would head a larger laboratory pursuing several lines of research
simultaneously and supported by a number of other scientists
both fully trained and undergoing postdoctoral training. These
individuals would also be supported by several technicians. As
techniques became more sophisticated and specialized, collabora-
tions between laboratories in order to do certain components of
the research also became much more common. In the last 10 y, we
are seeing the development of what can be termed mega science,
a good example of which is the human genome project. This
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type of approach is likely to continue to address speci¢c large
questions that cannot readily be approached in any other way,
but the results of the mega science may actually make it more
feasible for individuals in smaller laboratories to apply these re-
sults to their own speci¢c questions without the necessity for de-
veloping the infrastructure themselves. Thus, developments such
as the human and mouse genomes available on the Internet and
the development of chip technologies commercially available to
pursue genomic and proteomic type studies may, in the future,
facilitate the return to individual small to medium size labora-
tories focusing on speci¢c questions but able to tap into these
commercially and government supported general resources to
provide the wherewithal to pursue the studies.
WHAT
In the 1950s, most cutaneous biology research was focused on
common dermatologic diseases. This paralleled the interests of
the primarily M.D. dermatologist investigators. Mechanisms of
disease and mechanisms of treatment in patients and in specimens
derived from patients were the primary focus. This gave way in
the 1960s, 1970s, and 1980s to investigations of the molecular basis
of structure, function, and diseases of the skin. In the 1980s and
1990s, molecular genetics culminating with the human genome
project became the major thrust of many of these projects.With
the imminent completion of the human and mouse genomes and
with the emphasis on understanding how genes are translated
into structure and function, research is now shifting to genomics
and proteomics. This will be the major thrust for a period of
time, but as information develops the data will need to be inte-
grated into what is now being termed integrative biology, i.e., the
ability to assemble all of these many bits of information into an
understanding of how the cells and the organism function as a
whole. Another outgrowth of the genomics, prodeomics, and
integrative biology approaches will be a more rational approach
to the translation of this information into interventions in the
treatment of disease as well as diagnosis and prevention.
WHERE
In the 1950s, with Europe economically recovering from the
SecondWorldWar, as was Japan, most cutaneous biology research
took place in North America, the U.S.A. and Canada. In the
1960s, 1970s, and 1980s, European investigators and Japanese in-
vestigators progressively swelled the ranks of cutaneous biology
and continued to do so. Now with the globalization of trade
and science, research is worldwide but still is predominantly in
the technologically advanced societies. The worldwide expansion
of cutaneous biology research is likely to continue. There is some
concern that particularly interventional trials and research invol-
ving human subjects may tend to migrate to ThirdWorld coun-
tries with less strict controls over the welfare of human subjects
and where such expensive human subject research can be done
more cheaply. This aspect of globalization may be viewed as a
danger or as a bene¢t assuming su⁄cient human subject safety
can be assured as it maximizes the ability to get certain studies
done.
HOW
In the 1950s and 1960s, most cutaneous biology/dermatology
research was based on patient observation and the techniques
of light microscopy, biochemistry, and earlier immunologic ap-
proaches. This gave way to cell and tissue culture, which in the
last 20 or 30 y has progressively given way to the tools of mole-
cular biology, molecular genetics, and now chip technology as
applied to genetics, genomics, and prodeomics. The amount of
data being generated by these techniques is growing exponen-
tially and will require advances in bio-informatics in order to be
able to make sense of all the data and apply them to an integrated
knowledge of the function of the cell and the organism in health
and disease. Another future development will be the reemphasis
on clinical research, clinical trials, and outcome research, with the
application of new techniques and technology both in terms of
trial design and based on molecular and genetic knowledge, re-
sulting in the development of new interventions and diagnostic
and preventive procedures. In a sense, this will be coming full
circle going back to patient observation of the 1950s but with
the tools of the twenty-¢rst century.
In the 1950s, much of the cutaneous biology research was sup-
ported with clinical revenues within the departments of derma-
tology in which it was taking place. The NIH began supporting
such research in the 1950s and such research support was based as
much on the idea and the quali¢cations of the principal investi-
gator as on the speci¢c detailed approaches being employed. As
technology advanced and training became necessary in the use
of these technologies, NIH expanded its mechanisms for the sup-
port of the training of younger investigators as well as the sup-
port of newly trained investigators. This took the form of both
specialized project support mechanisms and career support me-
chanisms as well. These have been continuously re¢ned and ex-
panded as the enterprise has grown and the variety of approaches
has multiplied. In addition, NIH is making more and more use of
mechanisms to support larger science collaborations including
program project support, center support grants, and contracts for
the support of clinical trials, registries, and speci¢c reagent devel-
opment. Much of NIH’s support for the human genome project
has been through the contract mechanism. Nevertheless, particu-
larly in cutaneous biology, the bulk of NIH support for research
has been individual project grants and that is likely to be the case
for the foreseeable future. Other mechanisms will be applied as
appropriate in particular cases and when stimulation of certain
areas of the science is needed, such as support for registries and
support for training of individuals in epidemiology, health
sciences research, and outcomes research, but at least for cuta-
neous biology NIH support is likely to remain individual project
based along with support for postdoctoral training and early
career support.
The last 50 y have shown dramatic changes in cutaneous biol-
ogy research, in terms of who does the research, how the research
is done, and how the research is supported. Changes will con-
tinue into the twenty-¢rst century but we can all look forward
to continued government support of high level research in
cutaneous biology and the translation of ¢ndings to the care of
patients with skin diseases.
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